Compare AbCellera Biologics Inc (ABCL) vs Futu Holdings Ltd (FUTU) Price & Performance

ABCL trades at $11.36, up 0.71% today, with a bullish technical signal and strong analyst support. Recent Phase 2 trial success for ABCL635 drove a 33% intraday surge in August 2026, though the company reports negative net income margins and operating cash outflows. Revenue declined from $485M in 2022 to $75M in 2025, reflecting ongoing challenges in profitability despite clinical progress.

The stock offers upside to the $15.50 consensus price target but carries high risk due to persistent losses and cash burn. Investment appeal hinges on ABCL635's regulatory success and future revenue generation, while dilution from a $200M August 2026 offering and competitive pressures pose headwinds.

Futu Holdings (FUTU) trades at $118.08, down 1.01% today, with strong fundamental performance including 49.62% net margin and 30.8% ROE. Recent Q2 2026 earnings beat expectations with $3.33 EPS versus $2.98 estimate. Technical indicators show bullish momentum with support at $118 and resistance at $121. The company demonstrates robust revenue growth from $13.6B in 2024 to $22.85B in 2025, though faces multiple class action lawsuits alleging securities fraud during the 2023-2026 period.

Futu presents compelling valuation with P/E of 11.77 and bullish analyst consensus (58% buy ratings), targeting 32.6% upside potential. However, significant legal overhang from securities litigation and Q1 2026 earnings miss create near-term headwinds. The company's international expansion and strong ECM performance provide growth catalysts, but investors should weigh legal risks against fundamental strength.